clinical trial · NCT03571321
Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia
University of Chicago·phase1·recruiting·n = 15
Acute Lymphoblastic LeukemiaALL, ChildhoodALLRuxolitinibCyclophosphamideCytarabineMercaptopurineVincristinePegaspargaseRituximabMethotrexate (Intrathecal Administration)
brief summary
This study will test if adding ruxolitinib to standard multi-drug chemotherapy regimen will be safe and tolerated in adolescents and young adults with newly diagnosed Ph-like acute lymphoblastic leukemia (ALL).
started
May 28, 2019
primary completion
Sep 1, 2026
completion
Sep 5, 2027
last updated
Jan 9, 2026
official title
Phase I Trial of Ruxolitinib in Combination With a Pediatric Based-regimen for Adolescents and Young Adults (AYAs) With Ph-like Acute Lymphoblastic Leukemia (ALL)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol